Skip to content
10-Q

Quarterly Report

LIMINATUS PHARMA, INC. LIMN LIMNW

0001104659-26-062734

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 44.88M sh
Shares Diluted Q1 2026 · Mar 31, 2026 36M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 17.5M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.02M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$159.39K
Short Term Debt Q1 2026 · Mar 31, 2026 $1.44M
Short Term Debt Q1 2026 · Dec 31, 2025 $1.44M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$132.6K
Stockholders Equity Q1 2026 · Dec 31, 2025 −$9.81M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$19.67M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$19.34M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.89M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.3M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.33M
Current Assets Q1 2026 · Mar 31, 2026 $2.78M
Current Assets Q1 2026 · Dec 31, 2025 $500.57K
Total Assets Q1 2026 · Mar 31, 2026 $2.79M
Total Assets Q1 2026 · Dec 31, 2025 $512.8K
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$0.02
Eps Basic Q1 2026 · Mar 31, 2026 −$0.03
Eps Basic restated Q1 2026 · Mar 31, 2025 −$0.02
Sga Expense Q1 2026 · Mar 31, 2026 $700.9K
Sga Expense Q1 2026 · Mar 31, 2025 $264.22K
Rd Expense Q1 2026 · Mar 31, 2026 $400K
Net Income Q1 2026 · Mar 31, 2026 −$1.12M
Net Income restated Q1 2026 · Mar 31, 2025 −$327.53K
Operating Income Q1 2026 · Mar 31, 2026 −$1.1M
Operating Income restated Q1 2026 · Mar 31, 2025 −$264.22K